Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Cue Biopharma Reports Positive Phase 2 Topline Results for CUE-221 in Chronic ...

20 September 2026 · By · Wire by Fusion42

Published

20 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

China

◆ Source

Read at quiverquant.com →

◆ Verified

Fusion42 · 20 September 2026 · Fusion42 review

Cue Biopharma announced positive Phase 2 trial results for its drug CUE-221 in treating chronic spontaneous urticaria in China, showing statistically significant primary and secondary endpoints and a favorable safety profile compared to placebo and omalizumab.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a new standard of efficacy to beat in chronic spontaneous urticaria after Cue Biopharma’s CUE-221 outperformed omalizumab in key measures. Review your treatment differentiation now to protect or grow your market share.

◆ Coverage

1 source · 20 Sep 2026

◆ Related on Wire

◆ Topics

Biotechclinical-trialbiopharmachronic-urticariadrug-developmentcsupositive-results